Trevi Therapeutics raises ~$55M in private placement; amends SVB loan facility

Trevi Therapeutics, Inc.

Gross proceeds ~$55M from sale of 4.58M shares at $1.90/share and pre-funded warrants for 24.38M shares at $1.899.
Co-lead investors: Frazier Life Sciences and Venrock; also Fairmount and New Enterprise Associates participating.
Proceeds to fund clinical development of Haduvio for chronic cough in IPF patients and for working capital.
Loan amendment with SVB: upon raising $45M net equity, milestones terminate; interest rate becomes prime+3% (floor 6.25%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.